Desensitization to Hydroxychloroquine: 4 Cases

Caramaschi, Paola; Barbazza, Roberto; Tinazzi, Ilaria; Biasi, Domenico

doi:10.3899/jrheum.110345

Cited by 7 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…- Successful desensitization protocols to HCQ CADR (1 case for HCQ anaphylaxis) were reported with a daily dose of 0.1-400 mg/ml which was gradually increased during 36 days [6,52,53]; 1 case of systemic anaphylactic reaction with shock due to Qu was observed [54]. …”

Section: Discussionmentioning

confidence: 99%

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

et al. 2015

View full text Add to dashboard Cite

Background: Currently used antimalarial drugs (AM) are hydroxychloroquine and chloroquine, which are prescribed for many autoimmune disorders. The value of skin tests on cutaneous adverse drug reactions (CADR) with AM remains unknown. Objective: The main objective of this retrospective study is to know whether skin tests for AM are useful and how to manage the recovery of AM therapy in these patients. Methods: All patients referred for suspected CADR secondary to AM between 2001 and 2014 in eight French dermatology centers were retrospectively reviewed. Results: We report herein a retrospective series of 20 patients with CADR and AM involvement. Skin tests, performed in 14/20 patients, were negative in all cases. Six patients had an oral provocation test with recurrence of CADR in 1 case. Conclusion: We encourage dermatologists to perform oral provocation tests in nonsevere CADR in order to allow AM rechallenge at progressive doses.

show abstract

Section: Discussionmentioning

confidence: 99%

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

et al. 2015

View full text Add to dashboard Cite

show abstract

“…DPT is useful in nonsevere cutaneous ADRs in order to differentiate allergic reactions from dermatological adverse effects since only 30% of the patients reporting cutaneous ADRs reveal a positive DPT 90 . Successful desensitization protocols of hydroxychloroquine in MPE were reported 104‐107 . Recently, a 5‐hour desensitization protocol for nonimmediate urticaria was successfully administered 108 (Table 2).…”

Section: Antiviral And/or Immunomodulatory Drugs Used For Viral Pneummentioning

confidence: 99%

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

Gelincik

Brockow

Çelik

et al. 2020

Allergy

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID‐19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off‐label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off‐label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.

show abstract

“…DPT is useful in non-severe cutaneous ADRs in order to differentiate allergic reactions from dermatological adverse effects since only 30% of the patients reporting cutaneous ADRs reveal a positive DPT (87). Successful desensitization protocols of hydroxychloroquine in MPE were reported (101)(102)(103)(104). Recently, a 5-hour desensitization protocol for non-immediate urticaria was successfully administered (105).…”

Section: Hypersensitivity Reactionsmentioning

confidence: 99%

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19

Gelincik

Brockow

Çelik

et al. 2020

Preprint

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID-19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off-label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off-label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.

show abstract

Desensitization to Hydroxychloroquine: 4 Cases

Cited by 7 publications

References 2 publications

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19

Contact Info

Product

Resources

About